Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.

Biotechnology

Pharmaceutical

Prokaryotics

Keith Bostian

Holly Sutterlin

Terry Roemer

David Perlin

Brian Burr

Pamela Demain

Sang Ho Lee

Sherman Tim Waddell

The Scientific Advisory Board at Prokaryotics provides expert guidance on scientific strategy, research priorities, and development plans for the company's antibiotic programs. Comprised of seasoned scientists, the board evaluates emerging scientific trends, offers recommendations on optimizing early-stage drug development, and ensures alignment with industry standards and regulatory requirements.

Scientific Advisory Board

Scientific Advisory Team

Leadership Team

Scientific Advisory Board

About

Team members

Other teams at Prokaryotics

Scientific Advisory Team

Leadership Team